Headquarters


Grünenthal Group
Zieglerstraße 6
52078 Aachen
Germany

Phone: +49 241 569-0

Contact Form

Adverse Drug Reaction Reporting

 

 

Innovating at Scale: Gabriel Baertschi Interview Economist Intelligence Unit


In an interview with the Economist Intelligence Unit our CEO talks about Grünenthal’s ambition, explains why it is necessary to go for a network based approach in R&D and what his concept of leadership is all about.

Grünenthal Clinical Trial Portal

Grünenthal Group

The Grünenthal Group

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

Read more...

Societal Impact of Pain

Gabriel Baertschi addresses the improvement of pain policies in speech at Societal Impact of Pain symposium

Valletta, June 13, 2017 – During his speech at the Societal Impact of Pain symposium in Valletta, Malta, Gabriel Baertschi, CEO of Grünenthal and board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) emphasized the increased necessity of addressing the impact of pain on society. Not only is pain a major burden for those affected and one of the most common reasons for a doctor’s visit, but the societal burden of pain is also a major challenge for social systems in Europe. In the light of an aging society and an increasing number of chronic health conditions, a stronger focus on the societal impact of pain is necessary to secure excellent health care in Europe, in a long-term and sustainable manner.

Read more...